Posted by: Louis Provenzano | August 18, 2010

Novel Radio-peptide Targeted Therapy: Clinical Trials Approved

Excel Diagnostics & Nuclear Oncology Center is pleased to announce that after careful review the Federal Drug Administration (FDA) has approved Investigational New Drug Clinical Trial by LU-177 Octreotate for patients with Neuroendocrine cancers. Excel Diagnostics & Nuclear Oncology Center is the first research facility in North America to receive authorization to initiate this much needed cancer therapy.

This therapy can be applied to the category of neuroendocrine tumors which include Carcinoid, Islet Cell Carcinoma of the Pancreas, Oat Cell Carcinoma of the Lung, Pheochromocytoma, and Iodine refractory or Medullary Thyroid Carcinoma”.

The principle investigator of this program is Dr. Ebrahim S. Delpassand and the project is in collaboration with St. Luke’s Episcopal Hospital and Radio-Isotope Therapy of America (RITA) Foundation in Houston.

For further information regarding this treatment please contact Ms. Christiane Assir clinical coordinator (cassir@exceldiagnostics.com) of the project at: 713-341-3239.

We at Excel Diagnostics & Nuclear Oncology Center are proud to be part of yet another exciting therapy in the fight against Neuroendocrine cancers.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Categories

%d bloggers like this: